GeoVax Labs, Inc. (GOVX)
$0.64-$0.08 (-10.74%) Today
Robert T. McNally - DirectorGeovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 11 | 135,700 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
21 Form 4 filings on record, the earliest from Apr 1, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| John N. Spencer Jr. - Director | Grant or award | Stock Option | 6,000 | $0.00 | - | |
| Jayne Morgan - Director | Grant or award | Stock Option | 6,000 | $0.00 | - | |
| Robert T. McNally - Director | Grant or award | Stock Option | 6,000 | $0.00 | - | |
| Nicole Lemerond - Director | Grant or award | Stock Option | 6,000 | $0.00 | - | |
| Dean G. Kollintzas - Director | Grant or award | Stock Option | 6,000 | $0.00 | - | |
| Randal D. Chase - Director | Grant or award | Stock Option | 6,000 | $0.00 | - | |
| John W. Sharkey - Officer | Grant or award | Stock Option | 17,600 | $0.00 | - | |
| Mark Reynolds - Officer | Grant or award | Stock Option | 17,600 | $0.00 | - | |
| Mark J. Newman - Officer | Grant or award | Stock Option | 17,600 | $0.00 | - | |
| Kelly T. McKee Jr. - Officer | Grant or award | Stock Option | 17,600 | $0.00 | - | |
| David A. Dodd - Officer | Grant or award | Stock Option | 29,300 | $0.00 | - | |
| John N. Spencer Jr. - Director | Open-market purchase | Common Stock | 10,000 | $13.75 | $5K | |
| Kelly T. McKee Jr. - Officer | Open-market purchase | Common Stock | 1,107 | $16.75 | $742 | |
| John N. Spencer Jr. - Director | Grant or award | Stock Option | 10,000 | $0.00 | - | |
| Mark Reynolds - Officer | Grant or award | Stock Option | 70,000 | $0.00 | - | |
| Randal D. Chase - Director | Grant or award | Stock Option | 10,000 | $0.00 | - | |
| Robert T. McNally - Director | Grant or award | Stock Option | 10,000 | $0.00 | - | |
| Mark J. Newman - Officer | Grant or award | Stock Option | 70,000 | $0.00 | - | |
| David A. Dodd - Officer | Grant or award | Stock Option | 185,500 | $0.00 | - | |
| John N. Spencer Jr. - Director | Open-market purchase | Common Stock | 10,000 | $24.50 | $10K | |
| David A. Dodd - Officer | Open-market purchase | Common Stock | 10,000 | $27.00 | $11K |
GeoVax Labs, Inc. (GOVX) had 11 insider filings in the last 90 days, with the most recent on 2026-06-22. The full record for GOVX runs to 21 Form 4 filings, the earliest from 2025-04-01. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of GOVX were filed in the last 90 days. 4 purchases are on record for this company.
No insider sales of GOVX were filed in the last 90 days.
This page tracks GOVX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add GOVX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
